We are live on
!
Find out more
DCP
Davern Capital Partners Portfolio holdings
AUM
$587M
This Fund
S&P 500
This Quarter
Est. Return
+14.41%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$309M
AUM Growth
–
Cap. Flow
+$308M
Cap. Flow
% of AUM
99.45%
Top 10 Holdings %
Top 10 Hldgs %
90.61%
Holding
14
New
14
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$51.5M |
| 2 |
BioNTech
BNTX
|
+$37.4M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
+$35.6M |
| 4 |
Royalty Pharma
RPRX
|
+$32.1M |
| 5 |
argenx
ARGX
|
+$30.5M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
Similar funds
ROC
ETS
MWA
WPP
HNW
CFMC
WFA
RFG
Davern Capital Partners's Q4 2025 Portfolio in Review
Q4 2025 is the first quarter with a 13F filing on record for Davern Capital Partners, which disclosed 14 positions worth $309M. Its ten largest holdings account for 91% of the portfolio.
Its largest position is Pfizer: 2,042,242 shares worth $50.9M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets.
- Davern Capital Partners's largest Q4 2025 buy was Pfizer: 2,042,242 shares worth $50.9M.
- Davern Capital Partners's ten largest holdings make up 91% of its $309M portfolio in Q4 2025.
- Davern Capital Partners disclosed 14 positions in Q4 2025, its first 13F filing on record.
Based on Davern Capital Partners's 13F filing for Q4 2025, filed 13 Feb 2026.